“Scoliosis surgery is the most invasive procedure in spine. Now,
there is a minimally invasive alternative for many of these children and
adolescents,” said Prof. Yizhar Floman, M.D., Director of the Israel
Spine Center at Assuta Hospital, Tel Aviv, and past President of the
Israel Spine Society.

July 13, 2015 08:30 AM Eastern Daylight Time

CHARLESTON, S.C. & MISGAV, Israel--(BUSINESS WIRE)--ApiFix®
Ltd. announced today that the company’s ApiFix® system, which has
now been used to correct scoliosis in 50 adolescents since the system
was approved for marketing in Europe, continues to demonstrate
impressive results at one-to-three years of follow-up with 25 of these
patients.

“Scoliosis curve correction at one-to-three years follow-up is
substantial for these adolescents. Equally important, patients are
pain-free and happy with their new back shape. No implant failure has
been observed,” said Prof. Yizhar Floman, M.D., principal
investigator for the ApiFix® clinical study.

ApiFix® is a commercial-stage company that has developed the CE-markedApiFix®System — a non-fusion minimally invasive treatment
alternative for Adolescent Idiopathic Scoliosis (AIS). Scoliosis
surgery is the most invasive procedure in spine. The average procedure
fuses 10 vertebrae together using 20 screws, resulting in significant
and permanent loss of spine mobility.

“There is a dire need for an alternative to today’s standard for
scoliosis correction in adolescents 12 to 18 years old, the age when
rapid growth typically occurs,” said Uri Arnin, CEO,
headquartered in Misgav, Israel. “In 80 percent of these children, the
cause of their scoliosis is ‘idiopathic’, or unknown. While the
reduction in spine mobility is certainly a difficult consequence of long
spinal fusions, which are the gold standard of treating scoliosis today,
other critically important negative consequences include high chance for
back pain and additional spine surgery during the first 20 years
post-original surgery.”

“Now, there’s the ApiFix system,” added Ted Bird, Chairman, based in
Charleston, S.C., USA. “It is approved for sale in Europe. We are
currently raising funding in order to fast-forward our
sales-and-marketing efforts to launch a device that is designed to be a
new standard for correcting scoliosis in adolescents.”

A clinical study of The ApiFix® System led by Prof. Yizhar Floman, M.D.
past President of the Israel Spine Society, published this year in the
peer-reviewed medical journal Scoliosis concluded that
“there are many drawbacks to the current gold standard of AIS surgery,
which are almost nonexistent with the use of
ApiFix: considerable blood loss leading to blood
transfusions, neurologic deficit including spinal cord lesions, late
infections, pseudoarthrosis, limitation of spinal motion also affecting
non-fused levels, back pain and disc degeneration in the non-fused
spinal segments. Almost all of these
complications can be avoided by the use of Apifix.”